Defunct Company
Total Trials
15
As Lead Sponsor
14
As Collaborator
1
Total Enrollment
616
NCT00113438
Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors
Phase: Phase 2
Role: Lead Sponsor
Start: Mar 31, 2005
Completion: Feb 28, 2007
NCT01423149
Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
Completion: Jan 31, 2007
NCT00977210
Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors
Phase: Phase 1
Start: Jul 31, 2005
Completion: Not specified
NCT00395434
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
Start: Sep 30, 2006
NCT00507429
Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
Phase: Phase 2/3
Start: Aug 31, 2007
Completion: Nov 30, 2011
NCT00653939
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
Start: Mar 31, 2008
Completion: Oct 31, 2011
NCT00960557
Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden
Start: Jul 31, 2009
Completion: Oct 31, 2010
NCT01023295
Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)
Completion: Aug 31, 2010
NCT02132468
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
Start: Sep 30, 2014
Completion: Aug 31, 2016
NCT02055690
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
Phase: Phase 1/2
Role: Collaborator
Completion: Nov 24, 2017
NCT02279602
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
Start: Dec 31, 2014
NCT01701349
Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
Phase: Phase 3
Start: Mar 31, 2015
Completion: Dec 31, 2017
NCT02576301
Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
Start: Oct 31, 2015
Completion: Oct 31, 2020
NCT02641639
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer
Start: Jun 30, 2016
Completion: Oct 31, 2017
NCT05004753
A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects
Phase: Phase 4
Start: Sep 30, 2020
Completion: Apr 30, 2021